B. Metzler seel. Sohn & Co. AG Lowers Position in Edwards Lifesciences Corporation $EW

B. Metzler seel. Sohn & Co. AG lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 25.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,753 shares of the medical research company's stock after selling 14,264 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Edwards Lifesciences were worth $3,777,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of EW. Rehmann Capital Advisory Group boosted its holdings in shares of Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after acquiring an additional 130 shares during the period. Quadrant Capital Group LLC lifted its holdings in Edwards Lifesciences by 0.9% during the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company's stock worth $1,288,000 after purchasing an additional 136 shares in the last quarter. Stephens Inc. AR lifted its holdings in Edwards Lifesciences by 5.4% during the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock worth $239,000 after purchasing an additional 144 shares in the last quarter. Aspen Investment Management Inc boosted its stake in Edwards Lifesciences by 1.5% in the 4th quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company's stock worth $885,000 after purchasing an additional 150 shares during the period. Finally, Covestor Ltd grew its holdings in Edwards Lifesciences by 9.6% during the 4th quarter. Covestor Ltd now owns 1,784 shares of the medical research company's stock valued at $152,000 after buying an additional 157 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EW has been the topic of several analyst reports. UBS Group started coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price target on the stock. Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Mizuho upped their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. Finally, TD Cowen reiterated a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $100.27.

Edwards Lifesciences Stock Up 0.2%

Shares of NYSE EW opened at $90.00 on Friday. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The firm has a market capitalization of $51.82 billion, a PE ratio of 51.72, a price-to-earnings-growth ratio of 2.35 and a beta of 0.85. The firm has a fifty day simple moving average of $89.73 and a two-hundred day simple moving average of $85.49.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business's revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the firm's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel Lippis sold 619 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,045 shares of company stock valued at $457,749 in the last ninety days. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source